Skip to main content
. Author manuscript; available in PMC: 2022 Sep 7.
Published in final edited form as: Cell Rep. 2022 May 17;39(7):110814. doi: 10.1016/j.celrep.2022.110814

Figure 2. Antitumor immune response of AZD1775 is mediated via the cGAS-STING-TBK1-IRF3 pathway in SCLC.

Figure 2.

(A) Quantification of cells containing micronuclei (MN) after 1 μM AZD1775 treatment for 24 h. Bars represent mean ± SD of eight areas. Statistical significance was determined using Student’s t test (***p < 0.001).

(B) Western blots showing the protein expression of STING pathway, phospho (p)- and total (t)-STING, p- and t-TBK1, p- and t-IRF3, cGAS, and actin (loading control) in SCLC cells treated with 1 μM AZD1775 for 8, 24, and 48 h.

(C) Quantitative mRNA expression of IFN-α, IFN-β after treatment with 1 μM AZD1775 for 48 h in SCLC cells (H526, H82, H446, RPP, and RPM). Bars represent mean ± SD of triplicate. Statistical significance was determined using Student’s t test (**p < 0.01, ***p < 0.001).

(D and E) Quantitative mRNA expression of (D) CXCL10 and (E) CCL5 after treatment with 1 μM AZD1775 for 48 h in SCLC cells (H526, H82, H446, RPP, and RPM). Bars represent mean ± SD of triplicate. Statistical significance was determined using Student’s t test (**p < 0.01, ***p < 0.001).

See also Figures S2–S4.